ATXI vs. SXTP, INM, PALI, SPRB, AFMD, JAGX, GRI, ELAB, ADTX, and VCNX
Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include 60 Degrees Pharmaceuticals (SXTP), InMed Pharmaceuticals (INM), Palisade Bio (PALI), Spruce Biosciences (SPRB), Affimed (AFMD), Jaguar Animal Health (JAGX), GRI Bio (GRI), PMGC (ELAB), Aditxt (ADTX), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical products" industry.
Avenue Therapeutics vs. Its Competitors
Avenue Therapeutics (NASDAQ:ATXI) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.
Avenue Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -1,947.30%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Avenue Therapeutics' return on equity.
60 Degrees Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.
Avenue Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.79, suggesting that its share price is 179% more volatile than the S&P 500.
60 Degrees Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 195.36%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Avenue Therapeutics.
In the previous week, Avenue Therapeutics had 9 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 12 mentions for Avenue Therapeutics and 3 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 0.63 beat Avenue Therapeutics' score of -0.30 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.
17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 1.8% of Avenue Therapeutics shares are owned by insiders. Comparatively, 10.3% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
60 Degrees Pharmaceuticals beats Avenue Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Avenue Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avenue Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ATXI) was last updated on 7/2/2025 by MarketBeat.com Staff
Free ATXI Stock Alerts